Last €40.20 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 3:00 AM 04/10/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
€40.20
Previous Close
€40.20
Day High
€40.20
Day Low
€40.20
52 Week High
02/25/14 - €45.70
52 Week Low
01/8/14 - €36.06
Market Cap
45.0B
Average Volume 10 Days
3.2
EPS TTM
--
Shares Outstanding
1.1B
EX-Date
02/12/14
P/E TM
--
Dividend
€1.99
Dividend Yield
3.53%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the U.S. Food and Drug Administration accepted the filing of the New Drug Application for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes. If granted approval by the FDA, this combination will bring together, for the first time into one tablet, the distinct mechanisms of action of a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor. SGLT2 inhibitors remove excess glucose through the urine by blocking glucose re-absorption in the kidney. DPP-4 inhibitors work by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose. The filing follows the completion of a phase III clinical registration trial designed to evaluate the efficacy and safety of the empagliflozin/linagliptin combination compared to the individual components in adults with T2D. The Boehringer Ingelheim and Lilly Diabetes alliance plans to present data from this study later this year.

T1D Exchange and Eli Lilly and Company Announce Research Collaboration to Inform Development of New Initiatives to Advance Diabetes Care

T1D Exchange and Eli Lilly and Company announced they have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes, to identify new ways to improve care and advance outcomes. As part of this multi-year collaboration, the organizations will engage in a range of projects that combine Lilly's long history of and expertise in type 1 diabetes with T1D Exchange's innovative, patient-centric model that connects a clinic registry of more than 26,000 people with T1D, a clinic network comprised of more than 70 clinics across the U.S., a sample repository that stores patient biosamples and Glu, a patient and caregiver online community for T1D. The collaboration will involve multiple projects over an initial five-year period. The first project of the collaboration will assess user experience associated with insulin pumps and multiple daily injections. Initially, T1D Exchange data will be analyzed to inform development of a survey of health care providers from the clinic network and members of the Glu community. Following the survey, a study of clinic registry participants is planned, to further shed light on how insulin pumps are used and how multiple daily injections occur in real-world practice. Data and recommendations from this research will be shared publicly once analysis is complete, for the benefit of both the type 1 diabetes and researcher communities.

Jury Awards Compensatory and Punitive Damages to Plaintiffs in Case Against Eli Lilly and Company and Takeda Pharmaceuticals North America

Eli Lilly and Company responsed to the verdict in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America Inc., et al. No. 6:12-cv-00064. The jury found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Lilly. Under Lilly's agreement with Takeda, Lilly will be indemnified by Takeda for its losses and expenses with respect to the U.S. litigation and other related expenses in accordance with the terms of its indemnification agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:FP €40.20 EUR 0.00

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $38.93 USD +0.55
AbbVie Inc $48.55 USD +0.43
Amgen Inc $115.46 USD -0.08
AstraZeneca PLC 3,782 GBp +23.00
Teva Pharmaceutical Industries Ltd $50.85 USD +0.94
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 14.0x
Price/Sales 2.8x
Price/Book 3.7x
Price/Cash Flow 14.4x
TEV/Sales 2.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.